PHARMACEUTICALS related term(s) Drugs
Articles and editorials
Costly Oversight—Fine Print in GATT Law Could Cost Zantac Users Millions, S3582 [18AP]
Zantac Windfall, S3580 [18AP]
Bills and resolutions
Dept. of HHS: prepare and publish a consumer guide to prescription drug prices (see H.R. 3059), H2034 [8MR]
Diseases: establish a data bank of information on clinical trials and experimental treatments for all serious illnesses (see S. 2024), S9554 [2AU]
Drugs: review use of radiopharmaceuticals (see H.R. 3065), H2123 [12MR]
FDA: approval process and development of new drugs and biological products (see H.R. 3199), H3229 [29MR]
Federal Food, Drug and Cosmetic Act: certification of drugs containing insulin and antibiotics (see H.R. 3672), H6509 [18JN]
Health: development of pharmaceuticals relative to treatment for illegal drug addiction (see S. 2051), S9742 [3SE]
———regulation of pharmacists (see H.R. 3260), H3581 [17AP]
Medicare: coverage of certain antibiotics parenterally administered at home (see H.R. 4248), H11526 [27SE]
———eliminate time limitation on benefits for immunity suppressing drugs (see H.R. 3138), H2664 [21MR]
———pharmaceutical care services (see H.R. 3757), H7114 [8JY]
OPM: require annual reports to Congress on changes to Federal retiree health benefits (see S. 1759; H.R. 3462), S5093 [15MY], H5173 [15MY]
Patents: extend protection for certain pipeline drugs (see S. 2154), S11720 [28SE]
Prescription Drug Price Review Board: establish (see H.R. 3691), H6690 [20JN]
Research: reinstate reasonable pricing requirements for drugs developed with Federal funding or research and establish minimum levels of research reinvestment for drug manufacturers (see H.R. 4270), H11527 [27SE]
Tariff: HIV protease inhibitor chemicals (see S. 2021; H.R. 3977), S9554 [2AU], H9922 [2AU]
———pharmaceutical-grade phospholipids (see H.R. 4273), H11527 [27SE]
Taxation: extend certain tax provisions (see S. 1568), S1180 [9FE]
———suspension of tax on ozone-depleting chemicals used as propellants in metered-dose inhalers (see H.R. 3416), H4646 [8MY]
Letters
Changes to prescription drug policies under certain Federal retiree health benefits programs: several Members of Congress, E812 [15MY]
GATT implementation relative to generic drug industry: C. Everett Koop, S7120 [27JN]
———Carole A. Long, American Society of Tropical Medicine and Hygiene, S6597 [20JN]
———Daniel Perry, Alliance for Aging Research, S6597 [20JN]
———Eugene P. Schonfeld, National Kidney Association, S6598 [20JN]
———Joseph R. Bertino, American Association for Cancer Research, Inc., S6596 [20JN]
———Judith Simpson, United Patients' Association for Pulmonary Hypertension, Inc., S6597 [20JN]
———Nancy Sander, Allergy and Asthma Network/Mothers of Asthmatics, Inc., S6598 [20JN]
———Patti Munter, National Organization on Fetal Alcohol Syndrome, S6597 [20JN]
———Robert J. Beall, Cystic Fibrosis Foundation, S6597 [20JN]
———Sandra H. Kownacki, Autism Society of America, S6598 [20JN]
———several professors of medicine, S6596 [20JN]
———William E. Brock III, Brock Group, Ltd., S7120 [27JN]
GATT implementation relative to the generic drug industry: Cathy L. Hurwit, Citizen Action (organization), S3581 [18AP]
———Cynthia Pearson, National Women's Health Network, S3580 [18AP]
———Dixie D. Horning, S3581 [18AP]
———Generic Drug Equity Coalition, S3581 [18AP]
———Martha A. McSteen, National Committee To Preserve Social Security and Medicare, S3580 [18AP]
———Mern Horan, Consumer Federation of America, S3581 [18AP]
———Thair Phillips, Seniors Coalition, S3580 [18AP]
———Theresa Amato, Citizen Advocacy Center, S3581 [18AP]
Lists
Examples of Arkansas patents granted extensions under GATT, S7119 [27JN]
Remarks in House
Association of Food and Drug Officials: anniversary, E333 [13MR]
Dept. of HHS: prepare and publish a consumer guide to prescription drug prices (H.R. 3059), E317 [8MR]
FDA: approval process and development of new drugs and biological products (H.R. 3199), H5632-H5639 [29MY], E676 [1MY]
Health: accessibility of alternative treatments and medicines (H.R. 2019), H4115 [29AP]
———regulation of pharmacists (H.R. 3260), E558 [17AP]
Medicare: pharmaceutical care services (H.R. 3757), E1228 [9JY]
NIH: require private industry to enter into price agreements relative to the sale of drugs developed in cooperative research programs, H7335-H7337 [11JY]
OPM: require annual reports to Congress on changes to Federal retiree health benefits (H.R. 3462), E811 [15MY]
Research: reinstate reasonable pricing requirements for drugs developed with Federal funding or research and establish minimum levels of research reinvestment for drug manufacturers (H.R. 4270), E1788 [28SE]
Tariff: pharmaceutical-grade phospholipids (H.R. 4273), E1775 [28SE]
Remarks in Senate
Diseases: establish a data bank of information on clinical trials and experimental treatments for all serious illnesses (S. 2024), S9563 [2AU]
Drugs: patent protection for arthritis medication Lodine, S9457, S9458, S9463-S9466, S9469, S9499-S9501 [2AU]
FDA: regulation of prescription drug industry, S8457 [22JY], S8594-S8600, S8609-S8612 [24JY], S9336, S9337 [1AU]
———review of generic drug applications, S8546 [23JY]
GATT: implementation relative to generic drug industry, S3133, S3134 [28MR], S3215 [29MR], S3574, S3578-S3583 [18AP], S6460 [19JN], S6591-S6603 [20JN], S6827 [25JN], S7115-S7125 [27JN]
———implementation relative to generic drugs, S2038 [14MR]
Health: development of pharmaceuticals relative to treatment for illegal drug addiction (S. 2051), S9743 [3SE]
OPM: require annual reports to Congress on changes to Federal retiree health benefits (S. 1759), S5094 [15MY]
Patents: extend protection for certain pipeline drugs (S. 2154), S11720-S11722 [28SE]
———litigation relative to ranitidine, S2085 [14MR]
Tariff: HIV protease inhibitor chemicals (S. 2021), S9560 [2AU]
Taxation: extend certain tax provisions (S. 1568), S1182 [9FE]
Reports filed
Generic Drug Industry Relief: Committee on the Judiciary (Senate) (S. 1277) (S. Rept. 104-394), S12125 [1OC]
Statements
GATT Implementation Relative to Generic Drug Industry: by, S3134 [28MR]
———Michael Kantor, U.S. Trade Representative, S3215 [29MR]
Summaries
Tax Provision Extension (S. 1568), S1184 [9FE]
Texts of
S. 1568, tax provision extension, S1182-S1184 [9FE]
S. 2021, tariff on HIV protease inhibitor chemicals, S9561 [2AU]